Evidence map›Paper›PMID 32441910›Full record

ArticleACS applied materials & interfaces2020

Extracellular Vesicles Enhance the Remodeling of Cell-Free Silk Vascular Scaffolds in Rat Aortae.

Eoghan M Cunnane, Katherine L Lorentz, Aneesh K Ramaswamy, Prerak Gupta, Biman B Mandal, Fergal J O'Brien, Justin S Weinbaum, David A Vorp

Open access · greenAbstract read
In one paragraph

Article in ACS applied materials & interfaces, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. The Effect of Extracellular Vesicles on Thrombosis.Journal of cardiovascular translational research · 2023
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Eoghan M CunnaneDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.ORCID http://orcid.org/0000-0001-5599-9040
Katherine L LorentzDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.
Aneesh K RamaswamyDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.
Prerak GuptaDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.
Biman B MandalDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India 781039.ORCID http://orcid.org/0000-0003-3936-4621
Fergal J O'BrienTissue Engineering Research Group, Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland D02 YN77.ORCID http://orcid.org/0000-0003-2030-8005
Justin S WeinbaumDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.
David A VorpDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, United States.
University of Pittsburgh · USIndian Institute of Technology Guwahati · INRoyal College of Surgeons in Ireland · IE

Funding

Artificial Stem Cells for Vascular Tissue EngineeringR01HL130077 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VORP, DAVID ALAN · 2016 to 2019
$1.5M
Preclinical optimization and design for manufacturability of immunoregulatory tissue-engineered vascular graftsR61HL154102 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VORP, DAVID ALAN · 2020 to 2021
$757k
NHLBI NIH HHS R01 HL130077NHLBI NIH HHS R61 HL154102
6 · The paper itself

Abstract

Vascular tissue engineering is aimed at developing regenerative vascular grafts to restore tissue function by bypassing or replacing defective arterial segments with tubular biodegradable scaffolds. Scaffolds are often combined with stem or progenitor cells to prevent acute thrombosis and initiate scaffold remodeling. However, there are limitations to cell-based technologies regarding safety and clinical translation. Extracellular vesicles (EVs) are nanosized particles released by most cell types, including stem and progenitor cells, that serve to transmit protein and RNA cargo to target cells throughout the body. EVs have been shown to replicate the therapeutic effect of their parent cells; therefore, EVs derived from stem or progenitor cells may serve as a more translatable, cell-free, therapeutic base for vascular scaffolds. Our study aims to determine if EV incorporation provides a positive effect on graft patency and remodeling

Indexed as

AnimalsCells, CulturedExosomesExtracellular VesiclesHumansMesenchymal Stem CellsRatsSilkTissue EngineeringTissue ScaffoldsSilkaortic graftexosomesmesenchymal stem cellsmicrovesiclesvascular tissue engineering

Identifiers

PMID32441910
PMCPMC12039313
OpenAlexW3026908933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.